JOSD2 and non-small cell lung carcinoma: To further investigate the contribution of JOSD2 in NSCLC growth in preclinical settings, we used patient-derived cell (PDC) and patient-derived xenograft (PDX) models obtained from 3 cases of NSCLC patients harboring LKB1-WT (Fig. 6a).